On Thursday, shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc. recorded a trading volume of 3.36 million shares, which was above their three months average volume of 2.39 million shares. The stock ended the session 6.30% lower at $3.57. The Company's shares have gained 14.42% in the last one month and 6.25% in the previous three months. The stock is trading 6.98% below its 50-day moving average. Moreover, shares of Celldex Therapeutics, which develops, manufactures, and commercializes novel therapeutics for human health care in the US, have a Relative Strength Index (RSI) of 40.24.
On November 07th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock.
On November 29th, 2016, Celldex Therapeutics announced that it has completed its previously announced acquisition of Kolltan Pharmaceuticals, Inc., a privately held company focused on the discovery and development of novel, antibody-based drugs targeting receptor tyrosine kinases. Your complete research report on CLDX can be retrieved for free at:
Cranbury, New Jersey headquartered Amicus Therapeutics Inc.'s stock closed the day 3.01% lower at $5.80. A total volume of 6.61 million shares was traded, which was above their three months average volume of 2.38 million shares. The Company's shares are trading 18.69% below their 200-day moving average. Additionally, shares of Amicus Therapeutics, which focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases, have an RSI of 30.14.
On November 28th, 2016, Amicus Therapeutics announced its planned regulatory pathway to collect additional data to support full approval for the oral precision medicine migalastat for Fabry disease. Following several collaborative discussions with the U.S. FDA, including the receipt of final written minutes from an in-person Type B meeting, the Company plans to collect additional data on gastrointestinal symptoms in Fabry patients who have an amenable mutation. FOLD free report is just a click away at:
Shares in Dublin, Ohio Navidea Biopharmaceuticals Inc. recorded a trading volume of 1.89 million shares. The stock ended yesterday's trading session 8.47% lower at $0.72. The Company's shares have surged 125.97% in the previous three months. The stock is trading below its 200-day moving average by 13.71%. Furthermore, shares of Navidea Biopharma, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, have an RSI of 37.27.
On November 23rd, 2016, Navidea Biopharmaceuticals announced that it has entered into a definitive asset purchase agreement with Cardinal Health. Pursuant to the purchase agreement, Cardinal Health will purchase Navidea's Lymphoseek® product for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America. Navidea will receive $80 million at closing, plus the opportunity to earn up to $230 million of contingent consideration based on certain milestones through 2026, with $20.1 million of that amount guaranteed over the next 3 years. As part of the transaction, Cardinal Health will license a portion of the acquired intellectual property back to Navidea to allow Navidea to develop and sell new immunodiagnostic and immunotherapeutic products for specific purposes in North America, and to continue to produce and sell Lymphoseek, mostly under a different brand, outside of North America. Sign up for your complimentary research report on NAVB at:
Oakville, Canada headquartered Concordia International Corp.'s stock finished Thursday's session 3.11% lower at $2.49 with a total trading volume of 700,614 shares. Shares of the Company, which owns a portfolio of branded and generic prescription products in the US and internationally, are trading below their 50-day moving average by 32.37%. The stock has an RSI of 38.74.
On November 07th, 2016, Concordia International reported revenue of $185.5 million for Q3 2016, an increase of 99.5% over Q3 2015. For the reported quarter, the Company posted GAAP net loss from continuing operations of $75.1 million and GAAP loss per share of $1.47. Concordia International's net operating cash flows from continuing operations was $309.8 million for the nine month period ended on September 30th, 2016, compared to $67.9 million in the same period for 2015. Register for free on Stock-Callers.com and download the latest research report on CXRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA